<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66476">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02240472</url>
  </required_header>
  <id_info>
    <org_study_id>SENOMAC</org_study_id>
    <nct_id>NCT02240472</nct_id>
  </id_info>
  <brief_title>Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.</brief_title>
  <official_title>Survival and Axillary Recurrence Following Sentinel Node-positive Breast Cancer Without Completion Axillary Lymph Node Dissection - a Randomized Study of Patients With Macrometastases in the Sentinel Node</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the introduction of sentinel node biopsy in breast cancer, it has become clear that
      its use is reliable and reproducible. Today, it is clinical routine to not remove further
      lymph nodes from the axilla (arm pit) in case the sentinel node (which is the first lymph
      node/s reached by lymphatic flow from the breast) is free of tumor deposits. It is also
      routine to leave remaining lymph nodes behind in case the sentinel node contains a minimal
      cluster of tumor cells, called isolated tumor cells (formerly submicrometastasis). Even in
      slightly larger tumor deposits, so called micrometastasis (up to 2 mm in size), it has been
      shown that a completion axillary clearance (removal of further lymph nodes from the arm pit)
      does not contribute to a better survival. Data from a randomized study indicate that it
      seems safe to omit axillary clearance even if the sentinel node biopsy shows up to 2 nodes
      with tumor deposits over 2 mm in size (macrometastasis). These studies have changed clinical
      practice in many countries, however, it is still debated whether it is safe to omit axillary
      clearance in the case of sentinel node macrometastasis due to under-recruitment in the
      aforementioned study. The rationale for omitting extensive axillary surgery is the avoidance
      of postoperative morbidity such as arm lymphedema, loss of sensation, pain and swelling.

      The hypothesis is that refraining from axillary clearance in breast cancer patients with 1-2
      sentinel nodes with macrometastasis will not worsen breast cancer-specific survival by more
      than a maximum of 2.5% after 5 years.

      This study is a prospective multicenter randomized trial including the majority of centers
      in Sweden treating breast cancer. Planned accrual is 3700 patients.

      Breast cancer patients without signs of axillary nodal involvement will be eligible for
      sentinel node biopsy. Those who are found to have up to two sentinel node containing
      macrometastasis will be informed about this trial Those wishing to participate will be
      randomized to either undergo further axillary surgery (clearance) or not. Outcome measures
      are breast cancer-specific survival, disease-free survival, axillary recurrence rate and
      overall survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>breast cancer-specific survival</measure>
    <time_frame>up to 15 years</time_frame>
    <description>death due to breast cancer in both arms measured at a median follow-up of 5, 10 and 15 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5, 10 and 15 years</time_frame>
    <description>Breast cancer recurrence rate in both arms after a median follow-up of 5, 10 and 15 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>axillary recurrence rate</measure>
    <time_frame>5, 10 and 15 years</time_frame>
    <description>The rate of axillary relapse in specific after a median follow-up of 5, 10 and 15 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5, 10 and 15 years</time_frame>
    <description>The rate of overall deaths after a median follow-up of 5, 10 and 15 years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Axillary clearance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will be treated as is routine in Sweden today, namely, will undergo completion axillary clearance after a sentinel node biopsy showing 1-2 nodes with macrometastasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No axillary clearance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will not undergo further axillary surgery after a sentinel node biopsy showing 1-2 nodes with macrometastasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Omission of axillary clearance</intervention_name>
    <description>The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis</description>
    <arm_group_label>No axillary clearance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with invasive breast cancer ≤ 5 cm (T1-T2)

          -  N0 on palpation

          -  Pathology report shows macrometastasis in 1-2 sentinel lymph nodes

          -  Patients undergo segmental resection or mastectomy

          -  The patient must have provided oral and written consent

          -  Age ≥ 18 years

        Exclusion Criteria:

          -  Metastases outside of the ipsilateral axilla

          -  Neoadjuvant therapy

          -  Prior history of invasive breast cancer

          -  Pregnancy

          -  Bilateral breast cancer if one side meets exclusion criteria

          -  Medical contraindication for radiotherapy or systemic treatment

          -  Inability to absorb or understand the meaning of the study information; for example,
             through disability, inadequate language skills or dementia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jana de Boniface, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Frisell, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leif Bergkvist, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Hospital Västerås</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvette Andersson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Hospital Västerås</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Ryden, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malin Sund, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olofsson Roger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan Ahlgren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Örebro County</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jana de Boniface, PhD</last_name>
    <phone>+46851770000</phone>
    <email>jana.deboniface@karolinska.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leif Bergkvist, Professor</last_name>
    <phone>+4621173000</phone>
    <email>leif.bergkvist@ltv.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gävle sjukhus</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyula Nagy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Olofsson, PhD</last_name>
      <email>roger.olofsson@surgery.gu.se</email>
    </contact>
    <investigator>
      <last_name>Roger Olofsson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallands sjukhus</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann-Christin Källström</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsingborg lasarett</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Karin Falck</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kalmar sjukhus</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Sundqvist</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blekinge sjukhuset</name>
      <address>
        <city>Karlskrona</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Sjövall</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karlstad sjukhus</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Ohlsson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Hedin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malmö/Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Ryden, PhD</last_name>
      <email>lisa.ryden@skane.se</email>
    </contact>
    <investigator>
      <last_name>Lisa Ryden, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skaraborgs sjukhus</name>
      <address>
        <city>Skövde/Lidköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Nyman</last_name>
    </contact>
    <contact_backup>
      <last_name>Anja Lundberg</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana de Boniface, PhD</last_name>
      <phone>+46851770000</phone>
      <email>jana.deboniface@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Jana de Boniface, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Gerenal Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuat Celebioglu, PhD</last_name>
      <email>fuat.celebioglu@sodersjukhuset.se</email>
    </contact>
    <investigator>
      <last_name>Fuat Celebioglu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Norenstedt, PhD</last_name>
      <email>sophie.norenstedt@capiostgoran.se</email>
    </contact>
    <investigator>
      <last_name>Sophie Norenstedt, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sundsvall länssjukhus</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotta Wadsten</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uddevalla sjukhus</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carin Wångblad</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Malin Sund</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Wärnberg, PhD</last_name>
      <email>fredrik.warnberg@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Fredrik Wärnberg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Varbergs sjukhus</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Wallberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Västervik Hospital</name>
      <address>
        <city>Västervik</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Gustafsson, PhD</last_name>
      <email>peter.gustafsson2@ltkalmar.se</email>
    </contact>
    <investigator>
      <last_name>Peter Gustafsson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Västerås Central Hospital</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvette Andersson, PhD</last_name>
      <phone>+4621173000</phone>
      <email>yvette.andersson@ltv.se</email>
    </contact>
    <investigator>
      <last_name>Yvette Andersson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Wedin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://senomac.se</url>
    <description>study homepage</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 1, 2016</lastchanged_date>
  <firstreceived_date>September 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Jana de Boniface</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>sentinel node biopsy, lymph node metastasis, survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://senomac.se/Home/study%20protocol.html</doc_url>
      <doc_comment>Study protocol and patient information (English)</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
